Liposomal vincristine as a bridge therapy prior to CAR-T therapy in relapsed and refractory diffuse large B-cell lymphoma?

Juskaran Chadha, Shafinaz Hussein, Yougen Zhan, Jonah Shulman, Joshua Brody, Lynn Ratner, Amir Steinberg

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


We report a case of a 76-year-old male with a history of relapsed and refractory diffuse large B-cell lymphoma (DLBCL).Our patient was initially treated with front line chemotherapy along with central nervous system (CNS) prophylaxis with complete response. He subsequently relapsed, was sensitive to second-line chemotherapy, and underwent autologous stem cell transplantation achieving a complete remission. Only a few months after transplant, the patient suffered his second relapse and was deemed a candidate for Chimeric Antigen Receptor T-Cell Therapy (CAR-T). Given his aggressive disease, combined with the time needed to generate CAR-T cells, a multidisciplinary team recommended to treat our patient with liposomal vincristine in combination with rituximab as a bridge therapy. Durable responses have been seen using liposomal vincristine based on results from a recent phase II trial in heavily pretreated patients with DLBCL1. This therapy was effective in stabilizing and reducing active disease in our patient. This case looks to illustrate the use of liposomal vincristine in combination with immunotherapy in a novel setting bridging highly selected patients with active and refractory lymphoma prior to CAR-T. Moreover, we expanded an additional therapeutic point, highlighting the importance of optimal disease control prior to CAR-T cell harvesting, as recent literature has shown that residual malignant cells in the pheresis product may be inadvertently be transfected with the CAR gene, resulting in resistance and further relapse2.

Original languageEnglish
Pages (from-to)102-107
Number of pages6
JournalInternational Journal of Hematology-Oncology and Stem Cell Research
Issue number2
StatePublished - 2019


  • Autologous SCT
  • CAR-T
  • Heavily pretreated
  • Liposomal vincristine


Dive into the research topics of 'Liposomal vincristine as a bridge therapy prior to CAR-T therapy in relapsed and refractory diffuse large B-cell lymphoma?'. Together they form a unique fingerprint.

Cite this